Asset Details
Do you wish to reserve the book?
Is muscarinic receptor agonist effective and tolerant for schizophrenia?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Is muscarinic receptor agonist effective and tolerant for schizophrenia?
Do you wish to request the book?
Is muscarinic receptor agonist effective and tolerant for schizophrenia?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Is muscarinic receptor agonist effective and tolerant for schizophrenia?
2025
Overview
Background
Several randomized clinical trials (RCTs) have recently examined the efficacy and tolerability of muscarinic receptor agonists in schizophrenia. However, whether therapeutics targeting muscarinic receptors improve symptom management and reduce side effects remains systemically unexplored.
Methods
Embase, PubMed, and Web of Science were searched from inception until Jan 9, 2025. Altogether, the efficacy and safety outcomes of four RCTs (397 individuals in the muscarinic receptor agonists group, and 374 in the placebo control group) were meta-analyzed. To compare scores of positive and negative syndrome scale (PANSS), response rate, discontinuation rate, and adverse events with muscarinic receptor agonists vs. placebo in patients with schizophrenia, scale changes were pooled as mean difference (MD) for continuous outcomes and risk ratio (RR) for categorical outcomes.
Results
It revealed that muscarinic receptor agonists were superior to placebo in terms of decrease in the total PANSS score (MD, − 9.92; 95% CI, -12.46 to -7.37; I
2
= 0%), PANSS positive symptom subscore (MD, − 3.21; 95% CI, -4.02 to -2.40; I
2
= 0%), and PANSS negative symptom subscore (MD, -1.79; 95% CI, -2.47 to -1.11; I
2
= 48%). According to the study-defined response rate, the pooled muscarinic receptor agonists vs. placebo RR was 2.08 (95% CI, 1.59 to 2.72; I
2
= 0%). No significance was found in the discontinuation rate. Muscarinic receptor agonists were associated with a higher risk of nausea (RR = 4.61, 95% CI, 2.65 to 8.02; I
2
= 3%), and in particular, xanomeline-trospium was associated with risks of dyspepsia, vomiting, and constipation.
Conclusions
The findings highlighted an efficacy advantage with tolerated adverse event profiles for muscarinic receptor agonists in schizophrenia.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
Acetylcholine receptors (muscarinic)
/ Agonists
/ Analysis
/ Antipsychotic Agents - adverse effects
/ Antipsychotic Agents - therapeutic use
/ Bias
/ Complications and side effects
/ Dopamine
/ Humans
/ Materia medica and therapeutics
/ Medicine
/ Methods
/ Muscarinic Agonists - adverse effects
/ Muscarinic Agonists - therapeutic use
/ Nausea
/ Placebos
/ Randomized Controlled Trials as Topic
/ Schizophrenia - drug therapy
/ Trospium
